Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Melioidosis | 3 | 2018 | 50 | 1.38 | Why? |
| Drug Resistance, Multiple | 1 | 2021 | 156 | 0.83 | Why? |
| Wind | 1 | 2018 | 144 | 0.69 | Why? |
| Infusions, Parenteral | 1 | 2017 | 41 | 0.68 | Why? |
| Drug Resistance, Microbial | 1 | 2021 | 419 | 0.65 | Why? |
| Benchmarking | 1 | 2020 | 627 | 0.62 | Why? |
| Communicable Diseases | 2 | 2018 | 2148 | 0.49 | Why? |
| Housing | 1 | 2020 | 1146 | 0.48 | Why? |
| Climate Change | 1 | 2018 | 901 | 0.41 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.36 | Why? |
| Transients and Migrants | 1 | 2020 | 1468 | 0.36 | Why? |
| Communicable Disease Control | 4 | 2020 | 29620 | 0.33 | Why? |
| Travel | 2 | 2020 | 7220 | 0.28 | Why? |
| Singapore | 6 | 2020 | 3641 | 0.28 | Why? |
| Disease Outbreaks | 4 | 2021 | 27595 | 0.27 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.26 | Why? |
| Cross Infection | 3 | 2021 | 8675 | 0.25 | Why? |
| Global Health | 4 | 2020 | 13911 | 0.23 | Why? |
| Dengue | 3 | 2020 | 1565 | 0.23 | Why? |
| Voluntary Health Agencies | 1 | 2020 | 7 | 0.21 | Why? |
| Immunologic Factors | 1 | 2016 | 4206 | 0.20 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.20 | Why? |
| Platelet Transfusion | 2 | 2020 | 209 | 0.19 | Why? |
| Asia | 3 | 2017 | 2399 | 0.19 | Why? |
| Laos | 1 | 2018 | 144 | 0.19 | Why? |
| Cambodia | 1 | 2018 | 190 | 0.18 | Why? |
| Communicable Diseases, Emerging | 1 | 2013 | 2523 | 0.18 | Why? |
| Burkholderia pseudomallei | 1 | 2018 | 35 | 0.18 | Why? |
| Rain | 1 | 2018 | 108 | 0.17 | Why? |
| Povidone-Iodine | 1 | 2021 | 213 | 0.17 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.17 | Why? |
| Asia, Southeastern | 1 | 2018 | 390 | 0.17 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.16 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 2984 | 0.16 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.16 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.15 | Why? |
| Anti-Bacterial Agents | 2 | 2017 | 10083 | 0.15 | Why? |
| Thrombocytopenia | 2 | 2020 | 2093 | 0.14 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.14 | Why? |
| Emigration and Immigration | 1 | 2020 | 501 | 0.14 | Why? |
| Spatio-Temporal Analysis | 1 | 2020 | 1182 | 0.14 | Why? |
| Pharynx | 1 | 2021 | 1544 | 0.13 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.12 | Why? |
| Elective Surgical Procedures | 2 | 2021 | 5338 | 0.12 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.11 | Why? |
| Enterobacteriaceae Infections | 1 | 2017 | 529 | 0.11 | Why? |
| Surgery Department, Hospital | 1 | 2021 | 954 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Interferon-beta | 1 | 2016 | 979 | 0.10 | Why? |
| Humans | 24 | 2021 | 930598 | 0.10 | Why? |
| Anti-Infective Agents | 1 | 2021 | 1766 | 0.10 | Why? |
| Ribavirin | 1 | 2016 | 1182 | 0.10 | Why? |
| Orthopedic Procedures | 1 | 2020 | 1231 | 0.09 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.09 | Why? |
| Acute Disease | 1 | 2021 | 6029 | 0.09 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.09 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.09 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.08 | Why? |
| Leadership | 1 | 2020 | 2241 | 0.08 | Why? |
| Influenza, Human | 1 | 2011 | 10779 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.08 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.07 | Why? |
| Zika Virus Infection | 1 | 2018 | 1920 | 0.07 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.07 | Why? |
| National Health Programs | 1 | 2011 | 807 | 0.07 | Why? |
| Malaysia | 2 | 2020 | 1116 | 0.07 | Why? |
| Pregnancy | 2 | 2020 | 23879 | 0.07 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.07 | Why? |
| Surge Capacity | 1 | 2011 | 894 | 0.06 | Why? |
| Communication | 1 | 2020 | 5206 | 0.06 | Why? |
| Lopinavir | 1 | 2016 | 4308 | 0.06 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.06 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.05 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.05 | Why? |
| Vaccines | 1 | 2020 | 3692 | 0.05 | Why? |
| Female | 9 | 2020 | 380317 | 0.05 | Why? |
| Infection Control | 2 | 2021 | 23131 | 0.05 | Why? |
| Male | 9 | 2021 | 367725 | 0.05 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.05 | Why? |
| Enterobacter cloacae | 1 | 2017 | 58 | 0.04 | Why? |
| Orthopedic Surgeons | 1 | 2020 | 228 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.04 | Why? |
| Equivalence Trials as Topic | 1 | 2017 | 242 | 0.04 | Why? |
| beta-Lactam Resistance | 1 | 2017 | 150 | 0.04 | Why? |
| Mosquito Vectors | 1 | 2018 | 351 | 0.04 | Why? |
| Aedes | 1 | 2018 | 380 | 0.04 | Why? |
| Adult | 7 | 2021 | 244371 | 0.03 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.03 | Why? |
| Carbapenems | 1 | 2017 | 343 | 0.03 | Why? |
| Conjunctivitis, Viral | 1 | 2018 | 301 | 0.03 | Why? |
| Genome, Bacterial | 1 | 2017 | 446 | 0.03 | Why? |
| Escherichia coli Infections | 1 | 2017 | 348 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2017 | 835 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Climate | 1 | 2018 | 557 | 0.03 | Why? |
| Myalgia | 1 | 2018 | 1015 | 0.03 | Why? |
| Platelet Count | 1 | 2018 | 1381 | 0.03 | Why? |
| Klebsiella Infections | 1 | 2017 | 466 | 0.03 | Why? |
| Environment | 1 | 2018 | 769 | 0.03 | Why? |
| Klebsiella pneumoniae | 1 | 2017 | 658 | 0.03 | Why? |
| Middle Aged | 5 | 2021 | 270681 | 0.03 | Why? |
| Dengue Virus | 1 | 2018 | 910 | 0.03 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.03 | Why? |
| Escherichia coli | 1 | 2017 | 1547 | 0.02 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.02 | Why? |
| Latin America | 1 | 2014 | 1721 | 0.02 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2021 | 2844 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Zika Virus | 1 | 2018 | 1924 | 0.02 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Africa | 1 | 2014 | 2986 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3633 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.02 | Why? |
| Electronic Health Records | 1 | 2017 | 3492 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2016 | 51949 | 0.02 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.01 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.01 | Why? |
| Fever | 1 | 2018 | 7795 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Europe | 1 | 2014 | 12702 | 0.01 | Why? |
| Aged | 3 | 2018 | 215776 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
| Intensive Care Units | 1 | 2014 | 29594 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.01 | Why? |
| United States | 1 | 2014 | 46150 | 0.01 | Why? |
Fisher's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(137)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(95)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_